Atom­wise, On­coStatyx launch JV to tar­get triple-neg­a­tive breast can­cer; Can­cer biotech woos for­mer Spark COO John Furey

Celyad is team­ing up with Be The Match Bio­Ther­a­pies, a cell and gene ther­a­py so­lu­tions provider, on a clin­i­cal tri­al of its non-gene edit­ed al­lo­gene­ic CAR-T ther­a­pies. Be The Match Bio­Ther­a­pies will pro­vide the biotech with over 20 mil­lion vol­un­teer donors from their reg­istry of po­ten­tial blood stem cell donors, the source of start­ing ma­te­r­i­al for hematopoi­et­ic stem cell trans­plant and cel­lu­lar ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.